Clinical Trial Update: Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma [Phase 1]

View source ↗

Summary

This document reports on a Phase 1 trial evaluating the combination of ipilimumab and dabrafenib as first-line therapy for unresectable stage III/IV melanoma, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TAFINLAR (DABRAFENIB)
• Yervoy (ipilimumab)

Snippet

Sponsor: University of Utah | Conditions: Stage III or IV Melanoma | Phase 1 | Status: TERMINATED